Allogene Therapeutics, Inc.
NASDAQ:ALLO
2.13 (USD) • At close December 31, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Allogene Therapeutics, Inc. |
Symbool | ALLO |
Munteenheid | USD |
Prijs | 2.13 |
Beurswaarde | 446,601,360 |
Dividendpercentage | 0% |
52-weken bereik | 1.78 - 5.78 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. David D. Chang M.D., Ph.D. |
Website | https://www.allogene.com |
An error occurred while fetching data.
Over Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)